Navigation Links
Inhibition of NF-kappa B, a key inflammatory protein, reduced radiation toxicity in zebrafish
Date:9/1/2009

(PHILADELPHIA) Directly inhibiting the activity of a key protein mediator of inflammation reduced radiation toxicity in zebrafish embryos, and may ultimately be of help to patients receiving radiation therapy, according to researchers from the Kimmel Cancer Center at Jefferson.

Reporting in Molecular Cancer Therapeutics, the researchers found that inhibitors of NF-kappa B not only protected against radiation toxicity when given before exposure to treatment, but also lessened the radiation toxicity when given one to two hours post-exposure.

In the study, both NF-kappa B inhibitors and proteasome inhibitors were examined for their potential to alleviate the negative effects of radiation. However, the proteasome inhibitors tested, which included the FDA-approved bortezomib (Velcade), did not show the same effect. In fact, they actually exacerbated the harmful radiation effects.

"Although proteasome inhibitors demonstrate activity against NF-kappa B, they also target many other pathways," said Ulrich Rodeck, M.D., Ph.D., professor of Dermatology and Cutaneous Biology at Jefferson Medical College of Thomas Jefferson University. "We suspect that these agents may radiosensitize due to inhibition of these other targets."

This study was led by Dr. Rodeck and Adam Dicker, M.D., Ph.D., professor and interim chairman of the department Radiation Oncology at Jefferson.

"We started with the premise that NF-kappa B activity might be helpful in protecting cells against the harmful effects of radiation," Dr. Rodeck said. "We actually found quite the opposite - inhibiting the activity is an advantage that increased the survival in zebrafish and protected the individual organs from harmful effects of radiation."

According to Dr. Rodeck, the key is to downmodulate the NF-kappa B activity, rather than ablating it completely, as excessive NF-kappa B activation is potentially detrimental even in the absence of radiation therapy.

Drs. Rodeck and Dicker will be moving this research forward so that it may ultimately help individuals exposed to "dirty bombs," or cancer patients receiving radiation therapy. Their research team pioneered using zebrafish embryos as a vertebrate model system to investigate the effects of radiation therapy.


'/>"/>

Contact: Emily Shafer
emily.shafer@jefferson.edu
215-955-6300
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Proteasome inhibition affects epigenetic mechanisms
2. An effective strategy for inhibition of cirrhosis
3. Webinar on June 25 to Focus on Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
4. Researchers link inflammatory diseases to increased cardiovascular risk
5. Scientist at The Fienstein Instute for Medical Research Discovers Quitting Smoking Promotes Anti-Inflammatory Response
6. HerbalScience Research Identifies Specific Bioactives In Stabilized Rice Bran Extract that Impart Anti-Inflammatory Benefits
7. Study demonstrates the anti-inflammatory properties of pine bark extract
8. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
9. Oral/body inflammatory connection explained
10. Video: New Biological Therapy Ilaris(R) Approved in US to Treat Children and Adults with CAPS, a Serious Life-Long Auto-Inflammatory Disease
11. Drug May Help Against Inflammatory Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... ... Cellairis is a worldwide mobile device and computer repair franchise that is known ... Samsung Galaxy devices with premium parts and accessories. Cellairis has recently set-up for business ... customers. While customers do their shopping, Cellairis can accomplish a number of mobile device ...
(Date:12/9/2016)... ... December 09, 2016 , ... An inventor from Cana, ... safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP FOR ... easy to use and could be set up in a matter of minutes, or ...
(Date:12/9/2016)... Harrisburg, PA (PRWEB) , ... December 09, 2016 ... ... concussion education program through the Pennsylvania Cable Network (PCN) during the summer of ... Brain Injury Implementation Grant provided by the United States Department of Health and ...
(Date:12/8/2016)... ... 2016 , ... ZyDoc , a New York-based medical ... Capture Methods for Input to Electronic Health Records: A Comparative Usability Study” has ... usability study demonstrate that a dictation-based method (“NLP Entry”) using ZyDoc’s MediSapien™ natural ...
(Date:12/8/2016)... Boston (PRWEB) , ... December 08, 2016 , ... ... shareholders with global law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. ... sponsor of the DeviceTalks series, and attorneys from the firm’s global Life Sciences & ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)...  Eli Lilly and Company (NYSE: LLY ... EXPEDITION3 trial at the 9 th Clinical Trials ... did not meet the primary endpoint in the EXPEDITION3 ... with mild dementia due to Alzheimer,s disease (AD), and ... the treatment of mild dementia due to AD. ...
(Date:12/8/2016)... QUEBEC CITY , Dec. 8, 2016 /PRNewswire/ ... key US patents for improving the accuracy, reproducibility ... CD images in long and small bone orthopaedic ... proprietary approach to creating personalized orthopaedic restorations based ... create personalized orthopaedic restorations, the company harnesses the ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, ... has obtained proof-of-mechanism for neflamapimod (previously code named ... Phase 2a clinical trials that demonstrated significant Alzheimer,s ... 302 (12-week treatment) and Study 303 (6-week treatment) ... Trials in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: